Cour Pharmaceuticals Development News and Activities

View the org chart displaying its 16 main executives

Most searched biographies at Cour Pharmaceuticals Development

• Dannielle Appelhans, President and Chief Executive Officer
• John Puisis, Independent Director
• Nikhil Thatte, Director

Create your alert
to follow the executive moves at Cour Pharmaceuticals Development.

Cour Pharmaceuticals Development has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).

Popular M&A news in Pharmaceuticals

• Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
• Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
• Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).

Popular contacts in Pharmaceuticals

• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson
• Richard Saynor - Chief Executive Officer at Sandoz
• Robert Ford - Chief Executive Officer and Chairman of the Board at Abbott

Learn more about the Pharmaceuticals industry

Press releases by Cour Pharmaceuticals Development

• COUR Pharma Announces Positive One-Year Results from the Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
• COUR Pharma Publishes Peer-Reviewed Data in Science Advances
• COUR Pharma Secures FDA Orphan Drug Designation for CNP-106 in Generalized Myasthenia Gravis
• COUR Pharma Doses First Patient in Clinical Trial Evaluating CNP-103 in People Recently Diagnosed with Type 1 Diabetes
• COUR Pharmaceuticals Secures FDA Clearance of IND Application for CNP-103 in Type 1 Diabetes
• COUR Pharmaceuticals Enters Collaboration and Licensing Agreement with Genentech to Develop and Commercialize Tolerogenic Therapy for the Treatment of an Autoimmune Disease
• COUR Pharmaceuticals Doses First Patient in Phase 1b/2a Clinical Trial Evaluating CNP-106 in Generalized Myasthenia Gravis
• COUR Pharmaceuticals Announces Late-Breaking Poster for Phase 2a Data of CNP-104 in Primary Biliary Cholangitis Accepted for Presentation at The Liver Meeting® 2024
• COUR Pharmaceuticals Announces Positive Top-line Results from Phase 2a Study of CNP-104 in Primary Biliary Cholangitis
• COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
• View more press releases Close

Social media about Cour Pharmaceuticals Development

• Cour Pharmaceuticals Development on Wikipedia, Google News & Yahoo Finance
• Cour Pharmaceuticals Development on LinkedIn, X (Twitter) & YouTube